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Sickle haemoglobin comes of age 
Long marginalised as a disorder conﬁ ned to speciﬁ c racial 
groups, sickle-cell disease is now assuming its rightful 
place as a major global public health problem. Most 
patients in the Americas, the Caribbean, and much of 
Europe have been of one racial group, which led to the 
common misconception that the disease was conﬁ ned 
to people of African origin. Indeed, the mutation 
causing sickle haemoglobin (HbS) was noted on at least 
three separate occasions in Africa, and the associated 
polymorphisms are named after the regions where they 
were ﬁ rst described: Benin, Bantu, and Senegal.1 A fourth 
independent occurrence of the HbS gene is shared by 
people around the Gulf and in India where the prevalence 
of the trait exceeds 25% in many populations. The 
relative protection against falciparum malaria conferred 
by the HbS gene during a critical period of early childhood 
ensured a survival advantage and increasing prevalence 
over the generations. From this primary distribution, 
the gene was carried from west and central Africa to 
the Americas by the African slave trade, and latterly by 
voluntary migration mostly to the UK and Europe.
The extent and speed of this migration is the subject 
of an investigation by Frédéric Piel and colleagues in 
The Lancet Global Health.2 The investigators combined 
data from the World Bank’s Global Bilateral Migration 
Database of 232 countries with known HbS allele 
frequencies in the countries from which migration takes 
place and concluded that migration of individuals with 
HbS increased from 1·6 million in 1960, to 3·6 million in 
2000. The analyses are elegant but assume homogeneity 
in the distribution of the HbS gene in the donor 
countries, which might be broadly true in Nigeria, but 
not in countries such as Uganda and India, in which exist 
substantial tribal variations in trait frequency. In India, the 
HbS gene is widespread across Gujarat, Madhya Pradesh, 
Maharashtra, Chhattisgarh, and Odisha in central India, 
with a second focus in the north of Tamil Nadu and Kerala 
in southern India, reaching HbS frequencies as high as 
35%; however, the trait is largely conﬁ ned to the original 
tribal people living on the Deccan plateau, few of whom 
will participate in the emigration that traditionally takes 
place from major cities around the coast.
Notwithstanding these fairly minor concerns, an 
important implication of Piel and colleagues’ ﬁ ndings 
is that clinical services for patients will need to be 
greatly increased in countries with existing expertise, 
and developed in others without existing services. The 
structure of these clinical services will be established by 
local awareness, resources, and expertise. India again 
has shown that much can be achieved with political 
will, despite restricted resources, and three states in 
central India—Gujarat, Maharashtra, and Chhattisgarh—
already have sickle-cell control programmes, which have 
focused largely on population screening and monetary 
support. The mode of delivery of optimum care is 
still debated, but there are advantages in dedicated 
centres providing continuity of care, which can avoid 
the disruption of transition from paediatric to adult 
care3 during which many patients default from regular 
monitoring just as serious problems such as painful 
crises, leg ulceration, delayed growth and puberty, 
priapism, and pregnancy are emerging. Furthermore, 
a holistic approach to management has advantages, 
encouraging patients to attend earlier and reducing 
morbidity.4
The organisation of appropriate clinical services will 
need specialist expertise and training that could have 
been impeded by the absence of career structures in the 
specialty of non-malignant haematology. Debate even 
surrounds the most appropriate training for health-care 
personnel in sickle cell, on the basis that the required 
expertise is multidisciplinary, including infectious 
disease, pain management, psychosocial, and family 
counselling, and informed nurses or counsellors can 
have an important role for patients who often just need 
to discuss problems.
Other objectives in management involve prevention 
of serious complications, but also of the disease itself. 
Although presently incurable, much can be done to 
reduce morbidity and mortality from sickle-cell disease; 
because the greatest mortality is in the latter half the 
ﬁ rst year,4 early diagnosis is essential, preferably at birth. 
This ﬁ nding has led to the introduction of screening of 
newborn babies for sickle-cell disease, which is universal 
in the USA and the UK, and focused in perceived high-
risk groups in France; Brazil; Ontario, Canada; and the 
Caribbean. Once diagnosed, patients are monitored in 
specialised clinics and the family are made aware that 
the ﬁ rst clinical manifestation might be life-threatening. 
The other challenge will be in the education of patients 
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and carriers about the genetics and prevention of the 
disease. Sickle-cell disease results from the inheritance 
of abnormal genes from both parents and can be 
avoided if one parent has a normal (AA) haemoglobin 
genotype; the haemoglobin genotype then becomes 
one of many factors inﬂ uencing their choice of partner.
By contrast with a huge amount of scientiﬁ c literature 
addressing the pathophysiology, risk factors, and 
treatment of clinical manifestations of the disease, there 
is a dearth of epidemiology, which could contribute 
to our understanding, and Piel and colleagues’ article 
hints at the potential power of such approaches 
to the disease. Despite some daunting statistics in 
their report, a clear message is the need to deﬁ ne 
and provide optimum clinical services for patients, 
screening of newborn babies in countries where this is 
not yet available, and educational programmes that 
oﬀ er haemoglobin genotype detection and provide 
appropriate non-directional counselling. Such expertise 
is already available and can be drawn on by countries 
needing to develop these services anew. The rapidly 
changing genetic pattern of populations and the spread 
of the HbS gene from accelerating emigration demands 
services, but will also contribute positively to the cultural 
diversity of many societies.
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